These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. Jewell ML; McCauliffe DP J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400 [TBL] [Abstract][Full Text] [Related]
14. Topical tacrolimus therapy of resistant cutaneous lesions in lupus erythematosus: a possible alternative. Lampropoulos CE; Sangle S; Harrison P; Hughes GR; D'Cruz DP Rheumatology (Oxford); 2004 Nov; 43(11):1383-5. PubMed ID: 15266063 [TBL] [Abstract][Full Text] [Related]
15. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722 [TBL] [Abstract][Full Text] [Related]
16. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574 [TBL] [Abstract][Full Text] [Related]
17. [Disorders of conduction in lupus erythematosus : frequency and incidence in a group of 112 patients (author's transl)]. Godeau P; Guillevin L; Fechner J; Bletry O; Herreman G Ann Med Interne (Paris); 1981; 132(4):234-40. PubMed ID: 7305172 [TBL] [Abstract][Full Text] [Related]
18. [Fixed lupus erythematosus (its treatment with thalidomide)]. Barba Rubio J; Franco González F Med Cutan Ibero Lat Am; 1977; 5(4):279-85. PubMed ID: 364211 [TBL] [Abstract][Full Text] [Related]
19. Antinuclear antibodies related to acetylator phenotype in mice. Tannen RH; Weber WW J Pharmacol Exp Ther; 1980 Jun; 213(3):485-90. PubMed ID: 6970809 [TBL] [Abstract][Full Text] [Related]